In multiple sclerosis (MS), new data for Ocrevus (ocrelizumab) should help physicians understand the long-term characteristics of treatment with the monoclonal antibody.
First approved in the USA in 2017, Roche’s (ROG: SIX) blockbuster biologic took in over $4.5 billion sales last year, up by a quarter from the year before.
It is the first and only therapy approved for both relapsing MS (RMS) and primary progressive MS (PPMS), with six-month dosing.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze